Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 5/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.31 |
| ▸ | CDK2 | P24941 | 5/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29386248 | 0.88 | ALDH1A1 (0.41) | ADORA2AADORA1KDRAURKBHPGD | |
| SCHEMBL3960621 | 0.85 | SMN1; SMN2 (0.45) | HPGDTSHRHTTRAB9ASMN1; SMN2 | |
| SCHEMBL5144923 | 0.84 | KDM4E (0.47) | HPGDTSHRHTTRAB9ASMN1; SMN2 | |
| SCHEMBL3962781 | 0.83 | RAB9A (0.43) | KDRAURKBTSHRRAB9ASMN1; SMN2 | |
| SCHEMBL27157678 | 0.83 | KDM4E (0.49) | HPGDTSHRHTTRAB9ASMN1; SMN2 | |
| SCHEMBL4058424 | 0.83 | CDK1 (0.38) | KDRAURKBRAB9ASMN1; SMN2CDK1 | |
| SCHEMBL258582 | 0.81 | MAP3K5 (0.37) | HSP90AA1ABCB1PDPK1GDAALDH1A1 | |
| SCHEMBL4068517 | 0.81 | METAP2 (0.38) | KDRAURKBHTTRAB9ASMN1; SMN2 | |
| SCHEMBL11414187 | 0.80 | TP53 (0.46) | KDRAURKBHPGDMAPK1TSHR | |
| SCHEMBL4152240 | 0.78 | RAB9A (0.51) | HSP90AA1TSHRRAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368164-A1 | PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF | ASTROCYTE PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| EP-4329773-A1 | PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF | Astrocyte Pharmaceuticals, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-117241803-A | Purine nucleosides, intermediates and methods of making the same | 阿斯特罗赛特制药公司 | 2023-12-15 | — | — | CN | disclosed |
| WO-2022232810-A1 | PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| US-20090131651-A1 | Synthesis of 2-substituted adenosines | CBT DEVELOPMENT LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
| US-20080262214-A1 | Synthesis of 2-Substituted Adenosines | CAMBRIDGE BIOTECHNOLOGY LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1697393-A1 | IMPROVED SYNTHESIS OF 2-SUBSTITUTED ADENOSINES | BIOVITRUM AB (SE) | 2006-09-06 | — | — | EP | disclosed |
| EP-1694691-A1 | IMPROVED SYNTHESIS OF 2-SUBSTITUTED ADENOSINES | BIOVITRUM AB (SE) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005056571-A1 | IMPROVED SYNTHESIS OF 2-SUBSTITUTED ADENOSINES | BIOVITRUM AB (SE) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005054269-A1 | IMPROVED SYNTHESIS OF 2-SUBSTITUTED ADENOSINES | BIOVITRUM AB (SE) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262214-A1 | Synthesis of 2-Substituted Adenosines | ADORA3, ADORA1, ADORA2A | HSP90AA1 4332/4885ABCB1 200/4885ADORA2A 3/4885 |
| US-20240368164-A1 | PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF | NUDT1, PNP, UMPS | HSP90AA1 4038/4885ABCB1 1321/4885ADORA2A 23/4885 |
| US-20090131651-A1 | Synthesis of 2-substituted adenosines | ADORA3, NT5C2, RNGTT | HSP90AA1 4564/4885ABCB1 1018/4885ADORA2A 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.